Zika virus and HIV co-infection

Sookaromdee, Pathum; Wiwanitkit, Viroj

doi:10.1016/j.jfma.2018.07.006

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No data suggests that HIV infection might alter host susceptibility to or clinical manifestations of CHIKV infection [24]. Small epidemiological studies have reported few cases of ZIKV infection among PWH across different geographical regions, showing mild symptoms and reinforcing the higher probability of underreporting of asymptomatic cases [25][26][27]. Infection in women is a concern globally, mainly due to its association with congenital Zika syndrome, and behavioral factors such as the possibility of sexual transmission of ZIKV could contribute to the risk of ZIKV acquisition among PWH [28].…”

Section: Chikungunya and Zikamentioning

confidence: 99%

Endemic viral infections in immunocompromised hosts: Dengue, Chikungunya, Zika

Garnica,

Ramos,

Machado

2024

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of the review Arbovirus infections are a challenge for immunocompromised hosts who travel to or live in endemic regions or who receive organs or tissues from donors who travel or live in such areas. This review addresses Dengue (DENV), Chikungunya (CHIKV), and Zika (ZIKV) infections in hematological patients, hematopoietic cell or solid organ transplant recipients, and people with HIV (PWH). Recent findings Transmission is mainly due through Aedes mosquito bite. DENV and ZIKV may also be transmitted through blood, tissues or donor grafts. Clinical manifestations are quite similar and diagnosis requires laboratory confirmation to provide appropriate management. The best diagnostic method is PCR since serology may present false negative results in immunocompromised patients, or cross-reactivity as in the case of DENV and ZIKV. There is no specific treatment for any of these infections. Summary Educational and preventive measures are the best strategy: vector control, knowledge of the vector's habits, protection against mosquito bites, avoiding travel to endemic areas or with a current epidemic, and avoiding nonvector transmission according to local recommendations for donor deferral. Vaccination, currently only available for DENV, has not yet been studied in immunocompromised patients and is not currently recommended.

show abstract